Catalyst

Slingshot members are tracking this event:

Rigel (RIGL) Plans to Submit a New Drug Application for Fostamatinib in Immune Thrombocytopenic Purpura (ITP) in Q1 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RIGL

100%

Additional Information

Management Comment 3/07/2017: Rigel intends to submit the NDA in March
http://ir.rigel.com/...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 17, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fit Program, Chronic Itp, Blood Platelet Count, Immune Thrombocytopenic Purpura, Itp